---
title: "Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Budget impact"
description: "Formulary evidence on Deucrictibant (PHA121, PHA-022121) in On-demand treatment of hereditary angioedema attacks: Budget impact. Topics: Summary: acquisition prices of on-demand comparators; Summary: cost per attack, redosing, and annual costs; Summary: payer utilization management of on-demand agents; Summary: population and payer mix. 5 evidence topics quoted from 28 sources."
canonical: "https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary/budget-impact"
published: "2026-11-18T22:35:03-05:00"
modified: "2026-11-18T22:35:03-05:00"
---

# Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Budget impact

<a id="heading-1.1.3"></a>

## 1.1.3 Budget Impact of Deucrictibant

<a id="topic-1.1.3-1"></a>

### Summary

Pharvaris states in its 2026 Form 20-F that it does not have any drugs that have received regulatory approval, and in its third quarter 2026 discussion that it expects to recognize revenues from sales in 2027 if deucrictibant IR is approved for sale by the FDA. No wholesale acquisition cost, list price, or budget impact model for deucrictibant was identified. The company expects that its product candidates, if approved, will be priced at a “significant premium over competitive generic products”, and states that generic products expected over the coming years may create pricing pressure. Its third quarter 2026 expenses include build-out of a commercial organization, pricing research, and HAE market data supporting a potential launch of IR in 2027.

Source: [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm); [Pharvaris Form 6-K, third quarter 2026 MD&A (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_2.htm)

<a id="topic-1.1.3-2"></a>

### Summary: acquisition prices of on-demand comparators

- Oral sebetralstat (Ekterly): wholesale acquisition cost (WAC) at introduction on 2025-07-07 of $33,440.0000 for a pack of 4 tablets of 300 mg (California filing); the Missouri Medicaid fact blast states $8,360 per tablet, $16,720 per dose of two 300-mg tablets, and $33,440 per package of two doses. KalVista's 2026 Colorado disclosure states a WAC of $35,614 per carton of 4 tablets, and a California filing records a WAC at introduction of $35,614.0000 for a 4-tablet pack introduced 2026-09-21.
- Berinert 500 units: WAC of $4,442.47 effective 01/01/2026, up from $3,250.00 on 01/01/2021.
- Ruconest 2100 U, 1 carton: WAC of $8,075.00 effective 01/01/2025.
- Icatibant: the Sajazir manufacturer states that the WAC for Firazyr was $11,147.49 at its 2021 introduction. Generic icatibant WACs at introduction include $5,083.26 per single syringe (Teva, 2019-07-15), $1,000.00 per single syringe (AuroMedics, 2025-05-20), and $750.00 per single vial (Alembic, 2025-09-25).
- Federal Supply Schedule (FSS) and Big Four prices in the 2026 VA file: Firazyr 30 mg/3 mL, $9,522.98 FSS and $7,284.86 Big Four per syringe; generic icatibant, $979.90 FSS (NDC 63323-0574-86) and $2,317.97 FSS (NDC 00093-3066-34) per 3 mL syringe; Kalbitor 3 x 1 mL, $16,754.10 FSS and $12,431.63 Big Four; Berinert 500 IU vial, $3,217.25 FSS and $2,650.06 Big Four; Ruconest 2100 unit vial, $4,918.75 FSS and Big Four.
- Medicare Part B payment limits effective October 1 to December 31, 2026, based on 2Q26 ASP data: Berinert $79.329 per 10 units, Ruconest $37.810 per 10 units, and Kalbitor $599.616 per 1 mg.

Source: [California HCAI prescription drugs introduced to market (2025)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/80eea566-e1a0-4b62-884b-b0dfb58887e3/download/q1-q4-2025-prescription-drugs-introduced-to-market.xlsx); [MO HealthNet Ekterly fact blast (2025)](https://mydss.mo.gov/sites/mydss/files/media/file/2025/12/6c%20-%20Ekterly%20NDFB.docx); [KalVista Pharmaceuticals Colorado WAC disclosure (2026)](https://www.kalvista.com/wp-content/uploads/2026/05/Colorado-WAC-Disclosure-Ekterly-updated-20260504.pdf); [California HCAI prescription drugs introduced to market (2026)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/2be5663e-8862-42e8-bd0e-3476d8baf7c3/download/new-drug-data-jan-oct-2026.csv); [California HCAI five-year WAC increase history (2026)](https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/d754c567-c3c3-4ecf-a236-8144578549dd/download/5-year-wac-increase-history-jan-oct-2026.csv); [California HCAI WAC increase data (2025)](https://data.chhs.ca.gov/dataset/0c693b50-6d23-46a0-a1ae-7c320fe23dff/resource/46b78eef-5952-4fff-84c7-1fa758990ce8/download/q1-q4-2025-prescription-drug-wac-increases.xlsx); [California HCAI prescription drugs introduced to market (2021)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/5a80b890-24bb-4d66-a0bb-d6c46a150065/download/q1-q4-2021-prescription-drugs-introduced-to-market.xlsx); [California HCAI prescription drugs introduced to market (2019)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/6393cda0-6101-424e-b738-07aee9e6f94f/download/q1-q4-2019-prescription-drugs-introduced-to-market.xlsx); [Department of Veterans Affairs Federal Supply Schedule pharmaceutical prices (2026)](https://department.va.gov/procurement-acquisition-and-logistics/wp-content/uploads/sites/56/2026/11/TPharmPrices-11-01-2026.xlsx); [CMS Medicare Part B payment limit file (2026)](https://www.cms.gov/files/zip/october-2026-medicare-part-b-payment-limit-files-final.zip)

<a id="topic-1.1.3-3"></a>

### Summary: cost per attack, redosing, and annual costs

- Cost per attack: the 2018 ICER report states that on-demand medications range in cost from $5,000 to more than $12,000 per attack treated in the US. A US commercial payer decision model, with costs dated to 2019, estimated costs per attack of $12,905 for rhC1-INH, $14,806 for icatibant, $14,668 for pdC1-INH, and $21,068 for ecallantide. In an Italian cohort (Italian National Health Service perspective), the average cost per attack was €1183 (SD €789), €1069 with pdC1-INH and €1651 with icatibant (unadjusted).
- Redosing: the Missouri Medicaid fact blast reports redosing in 13% to 38% of episodes with sebetralstat, 7% to 44% with icatibant, 8% to 30% with Berinert, 6% to 18% with Kalbitor, and 2% to 10% with Ruconest. The NICE draft guidance records additional dosing rates of 22.25% for sebetralstat (KONFIDENT-S), 8.91% for icatibant, 18.18% for Cinryze and Ruconest, and 1.11% for Berinert. Cigna states that the second rescue dose was given for 39.8% of Ekterly-treated attacks. The ICER model used extra-dose percentages of 1.9% (Berinert), 12.0% (Kalbitor), 12.7% (Firazyr), and 6.6% (Ruconest).
- Annual costs: modeled on-demand-only treatment in a patient survey carried direct costs of $363,795 and indirect costs of $52,576 per patient per year, with medications at $227,674 (62.5%). In claims data for 328 patients, mean annualized HAE-related healthcare costs were $165,348 before and $515,333 after starting long-term prophylaxis, and 67% had at least 1 post-index on-demand therapy claim; on-demand pharmacy costs among patients with at least 1 claim were $217,857 pre-index and $167,462 post-index per patient per year. In an analysis of a commercial claims database across the United States, on-demand therapy spend in 29 on-demand-experienced members declined by an average of $47,358 per member after starting long-term prophylaxis, with allowed cost per member of $108,748 before and $61,390 after (-43.6%). Kutrieb et al. (2026) report annualized expenditures for on-demand prescriptions, hospitalizations, and ED visits averaging more than $200,000 even after initiation of subcutaneous long-term prophylaxis.
- Acute care unit costs: mean HAE ED visit costs were $1479 (95% confidence interval, $1028-1929) in the 2006-2007 Nationwide Emergency Department Sample.

Source: [ICER final evidence report (2018)](https://icer.org/wp-content/uploads/2020/10/ICER_HAE_Final_Evidence_Report_111518-1.pdf); [Bernstein et al. (2019)](https://pmc.ncbi.nlm.nih.gov/articles/PMC10391298/); [Federici et al. (2018)](https://pmc.ncbi.nlm.nih.gov/articles/PMC6067408/); [MO HealthNet Ekterly fact blast (2025)](https://mydss.mo.gov/sites/mydss/files/media/file/2025/12/6c%20-%20Ekterly%20NDFB.docx); [NICE sebetralstat draft guidance (2025)](https://www.nice.org.uk/guidance/gid-ta11334/documents/draft-guidance); [Cigna Ekterly drug quantity management policy (2026)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_934_coveragepositioncriteria_hae_ekterly_dqm_per_days.pdf); [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/); [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/); [Heuring et al. (2026)](https://www.primetherapeutics.com/documents/d/primetherapeutics/EVT_EXT_670100-H_AMCPPstr_RealWorldPatternsOfOnDemandUtilization_R4-2_Web); [Kutrieb et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13151981/); [Zilberberg et al. (2011)](https://pubmed.ncbi.nlm.nih.gov/22195693/)

<a id="topic-1.1.3-4"></a>

### Summary: payer utilization management of on-demand agents

- Cigna (review date 07/08/2026) sets Ekterly quantity limits sufficient to treat 4 attacks at the maximum dose per 28 days, with an override for an additional 4 attacks each month.
- Univera Healthcare requires, for patients 18 years and older, documentation of therapeutic failure, severe intolerance, or a contraindication to generic icatibant before Ekterly, with a quantity limit of 4 tablets per 30 days; brand Firazyr also requires documentation regarding a trial of generic icatibant, and only one acute HAE medication is authorized at one time.
- Regence (effective April 1, 2026) requires documentation that generic icatibant and at least one of Berinert or Ruconest have been ineffective, not tolerated, or contraindicated, authorizes acute treatments in a quantity sufficient for three attacks per month, and states that generic icatibant is the lowest cost of all available options.
- CountyCare's medical benefit guideline covers Berinert (J0597), Firazyr (J1744), Kalbitor (J1290), and Ruconest (J0596), and requires trial and failure or intolerance of the preferred product for non-preferred requests.
- MO HealthNet prior authorization for Ekterly requires use for on-demand treatment of acute HAE attacks, with an initial approval period of 6 months; its fact blast lists deucrictibant with a phase III trial (NCT06669754) and an estimated completion of August 2026; the sponsor identifies NCT06669754 as CHAPTER-3, its trial of deucrictibant XR for prophylaxis.

Source: [Cigna Ekterly drug quantity management policy (2026)](https://static.cigna.com/assets/chcp/pdf/coveragePolicies/cnf/cnf_934_coveragepositioncriteria_hae_ekterly_dqm_per_days.pdf); [Univera Healthcare hereditary angioedema pharmacy policy (2026)](https://www.univerahealthcare.com/documents/d/global/hereditary-angioedema-hae-pdf); [Regence medication policy dru535 (2026)](https://regence.myprime.com/content/dam/prime/memberportal/forms/AuthorForms/Cambia/Program_Summaries/dru535reg.pdf); [CountyCare acute HAE products guideline (2026)](https://countycare.com/wp-content/uploads/ECG_5000.CC-for-Acute-Hereditary-Angioedema-Products-ver-Jan-26.pdf); [MO HealthNet Ekterly fact blast (2025)](https://mydss.mo.gov/sites/mydss/files/media/file/2025/12/6c%20-%20Ekterly%20NDFB.docx); [Pharvaris Form 6-K, third quarter 2026 results (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000119312526456847/phvs-ex99_1.htm)

<a id="topic-1.1.3-5"></a>

### Summary: population and payer mix

- US diagnosed population: a claims-based algorithm estimated 9559, 9341, and 8694 people diagnosed with HAE in 2018, 2019, and 2020 (2.67, 2.61, and 2.43 per 100,000), and expert physician analysis estimated 7602, 7275, and 6595. Castaldo et al. (2021) state that HAE due to C1 inhibitor deficiency affects fewer than 8000 people in the United States. The Pharvaris 20-F cites HAE International, as of October 2014, for at least 7,000 patients in the U.S. and at least 15,000 in the EU.
- Treatment pattern: of 737 survey respondents, 37.3% (n = 275) were prescribed and using on-demand-only treatment. Tachdjian et al. (2026) state that approximately 70% of US patients with HAE are treated with long-term prophylaxis.
- Payer mix: The California filing for sebetralstat states marketing investments organized to reflect a payer mix of 70% commercial payors, 25% Medicare Part D, and 5% Medicaid, with an estimated 780 patients in the 2025 filing and 7500 in the 2026 filing.
- Medicare Part D spending in 2024 was $43713828.6 for Firazyr (170 beneficiaries), $32477428.42 for generic icatibant (658 beneficiaries), $34597556.94 for Berinert (63 beneficiaries), $55710878.24 for Ruconest (128 beneficiaries), and $20871584.35 for Kalbitor (36 beneficiaries).

Source: [Castaldo et al. (2025)](https://pubmed.ncbi.nlm.nih.gov/40414286/); [Castaldo et al. (2021)](https://pmc.ncbi.nlm.nih.gov/articles/PMC8133018/); [Pharvaris Form 20-F (2026)](https://www.sec.gov/Archives/edgar/data/1830487/000183048726000013/phvs-20251231.htm); [Tachdjian et al. (2026)](https://pmc.ncbi.nlm.nih.gov/articles/PMC13273463/); [California HCAI prescription drugs introduced to market (2026)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/2be5663e-8862-42e8-bd0e-3476d8baf7c3/download/new-drug-data-jan-oct-2026.csv); [California HCAI prescription drugs introduced to market (2025)](https://data.chhs.ca.gov/dataset/e54d331c-65d3-4c6e-b4ba-390bd7024248/resource/80eea566-e1a0-4b62-884b-b0dfb58887e3/download/q1-q4-2025-prescription-drugs-introduced-to-market.xlsx); [CMS Medicare Part D Spending by Drug (2026)](https://data.cms.gov/sites/default/files/2026-06/98218f98-166c-4723-8438-c344a4ef96a6/DSD_PTD_RY26_P04_V10_DY24_BGM.csv)

## Related pages
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Terms and abbreviations](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/terms-and-abbreviations.md)
- [Deucrictibant (PHA121): On-demand treatment of hereditary angioedema attacks](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/executive-summary.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Product information and disease description](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/product-information-and-disease-description.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Clinical evidence](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/clinical-evidence.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: Economic information and modeling report](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/economics.md)
- [Deucrictibant (PHA121) in On-demand treatment of hereditary angioedema attacks: References](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references) · [Markdown](https://www.evicenter.com/drugs/deucrictibant--on-demand-treatment-of-hereditary-angioedema-attacks/references.md)
